文献速递免疫规划卫生政策与健康促进

日本青少年百日咳加强疫苗接种的成本效果分析

Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan.
PubMed 文献 · Vaccine · 2024-02-27

研究评估日本11岁青少年用百白破疫苗(DTaP)替代白破疫苗(DT)的成本效果,并分析接种青少年对未接种婴儿弟妹的间接保护作用。采用高发病与低发病两种百日咳病例情景,计算增量成本效果比(ICER)。高发病情景下ICER为每获得一个质量调整生命年(QALY)4,254,515日元,低发病情景下为62,546,776日元。结论认为成本效果受百日咳发病水平影响,高发病情景下ICER更有利,间接效应影响较小。

要点

  • 高发病情景下DTaP替代DT的ICER为每QALY 4,254,515日元。
  • 低发病情景下ICER为每QALY 62,546,776日元。
  • 敏感性分析显示百日咳效用值对ICER影响最大。

核心结论

  • 用DTaP疫苗替代DT疫苗的成本效果受百日咳发病水平影响,高发病情景下ICER更有利。
  • 接种青少年对未接种婴儿弟妹的间接效应对ICER影响较小。
  • 作者建议政策制定者应持续监测后COVID-19时代的百日咳流行趋势,并根据感知趋势决定是否引入加强针。

研究设计与样本

  • 研究基于经济模型,包含青少年和婴儿子模型,评估DTaP策略相对于DT策略的增量成本效果比(ICER),以质量调整生命年(QALYs)为效果指标。
  • 高发病情景采用2019年百日咳病例数,低发病情景采用2020-2021年平均病例数。
  • 婴儿的间接效应建模为未接种婴儿从已接种的青少年兄姐处避免百日咳感染的概率。

主要发现

  • 从支付者角度,高发病情景下ICER为每获得一个QALY 4,254,515日元,低发病情景下为每获得一个QALY 62,546,776日元。
  • 间接效应对ICER的影响较小。

临床怎么用

  • 作者建议政策制定者应持续监测后COVID-19时代的百日咳流行趋势,并根据感知趋势决定是否引入加强针。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In Japan, the introduction of a fifth diphtheria-tetanus-acellular pertussis (DTaP) vaccination has been considered, and adolescents aged 11-12 years old who are currently receiving the diphtheria-tetanus (DT) vaccine are one candidate group. We analyze the cost-effectiveness of replacing the DT vaccine with the DTaP vaccine for 11-year-old adolescents and investigate the indirect effect of vaccinated adolescents on unvaccinated infant siblings. We undertake two analyses using high- and low-morbidity pertussis cases, and based on the results, present suggestions for pertussis prevention in the post-COVID-19 pandemic era. METHOD: We used the number of pertussis cases in 2019 as the high-morbidity case and the average number of cases in 2020-2021 as the low-morbidity case, and evaluated the incremental cost-effectiveness ratio (ICER) of the DTaP strategy to the DT strategy based on quality-adjusted life years (QALYs). The economic model contained adolescent and infant sub-models. The indirect effect for infants was considered as the probability of unvaccinated infants avoiding pertussis infection from their vaccinated siblings. RESULTS: The ICER from the payers' perspective was Japanese yen (JPY) 4,254,515 per QALY gained in the high-morbidity case and JPY 62,546,776 per QALY gained in the low-morbidity case. The sensitivity analysis showed that the utility of pertussis had the greatest impact on the ICER, with a 60.58% and 0% probability that the ICER was less than JPY 5 million per QALY gained in the high-morbidity case and low-morbidity case, respectively. CONCLUSION: The cost-effectiveness of replacing the DT vaccine with the DTaP vaccine is affected by the level of pertussis morbidity, with the ICER becoming more favorable in the high-morbidity case. The indirect effect has little impact on the ICER. Thus, policy-makers should continue to monitor the pertussis epidemic in the post-COVID-19 era, and determine the need to introduce a booster based on perceived trends.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tanaka M, Okubo R, Hoshi SL, et al. Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan. Vaccine. 2024. PMID: 38418340. doi:10.1016/j.vaccine.2024.02.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。